


Harness the Power of YourPDX™ Functional Precision Oncology

An Observational Clinical Research Study to Help Identify Therapeutic Options

YourPDX testing is an advanced approach to functional precision oncology. At Certis, this type of personalized in-life testing involves custom-developing orthotopic patient-derived xenograft (O-PDX) models of an individual's cancer – living replicants of a person's tumor in specialized research mice. The mouse models function as the individual's avatars in the laboratory, allowing Certis to test and evaluate multiple drugs or drug combinations.



ORTHOTOPIC = SITE OF ORIGIN

“

To know that I presently have a drug that is impacting the tumor and potentially four more in reserve is a game changer. I cannot tell you the impact this has had on my family and me.”

”

— Jeff Dinkin

Certis Oncology Solutions is a life science technology company with a mission to connect every cancer patient to the optimal therapy the first time, every time. Our product is Certis Oncology Intelligence™—highly predictive therapeutic response data derived from proprietary biological models of cancer. We serve cancer patients and their treating oncologist through personalized functional testing, and indirectly, by helping innovators develop the next generation of oncology therapeutics.



YOURPDX TESTING REQUIRES FRESH TUMOR TISSUE. IT IS ESSENTIAL TO CONTACT US PRIOR TO BIOPSY OR RESECTION SURGERY.

YOURPDX IS A FUNCTIONAL TEST THAT MEASURES THERAPEUTIC RESPONSE IN PERSONALIZED PDX MODELS. TEST RESULTS ARE NOT A REPLACEMENT FOR MEDICAL ADVICE. TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PATIENTS AND THEIR PHYSICIANS.



858-228-4119

ClinicalServices@certisoncology.com

certisoncology.com

©2023 Certis Oncology Solutions, Inc. All Right Reserved.

CERTIS™ ONCOLOGY
INTELLIGENCE



What's Next in Your Cancer Treatment Journey?

Be Armed with Options.

YOURPDX™
FUNCTIONAL PRECISION ONCOLOGY

Undergoing treatment for complex cancer can feel like an exercise in trial and error... especially when first- or second-line treatment fails—or an individual's cancer becomes resistant to a previously effective regimen.

Without a generally accepted standard of care, individuals with cancer and their oncologists may decide between a multitude of possible off-label drug combinations and investigational drugs that may be available in clinical trials.^{1,2} Over the course of their illness, it is common for individuals with cancer to undergo several different lines of therapy (LoT), often with difficult side effects and sometimes with little or no therapeutic benefit.


The trial-and-error approach to clinical decision-making may rob individuals with cancer of the two things they need most: strength to fight, and time. **At Certis, we believe we must—and can—do better.**

When to Consider YourPDX Testing

In a case where an individual with primary or metastatic cancer does not respond to first- or subsequent lines of treatment, develops resistance to a previously effective therapy, or experiences recurrence after successful treatment, YourPDX testing is a viable option to pursue.

YourPDX testing is performed while an individual with cancer simultaneously undergoes their prescribed therapy and takes an average of four to six months to complete.

Bringing Greater Certainty to Precision Medicine



Tumor Volume Over Time in Response to Multiple Therapeutic Options

By replicating an individual's cancer in mice, Certis can test multiple therapeutic options simultaneously to understand how that individual's personalized mouse avatars will respond to each potential treatment.

• Genetic Testing Alone Is Not the Answer

Although tumor genomic profiling has become mainstream oncology practice, a surprisingly small number of individuals with cancer currently derive clinical benefit from sequence-driven therapy.^{3,4}

There are varied reasons for this:

- Sequencing sometimes identifies no potentially actionable mutations.
- There are often no available therapies that target identified mutations.
- Many cancer phenotypes, including those that influence response to therapy, are determined by non-genetic mechanisms.

While genetic profiling alone may not realize the promise of precision medicine, this data is still incredibly valuable, especially when combined with functional testing. Tumor genomics can help inform which treatment options to include in an individual's YourPDX study design.

1. Saiyed MM, et al. *J Clin Pharm Ther.* Jun 2017
2. Unger JM, et al. *J Clin Oncol.* 2021

3. Cobain et al *JAMA Oncol.* 2021
4. Flaherty, et al. *J Clin Oncol.* Nov 20, 2020